Oncternal Operating Income from 2010 to 2024
| ONCT Stock | USD 0.71 0.43 37.72% |
Operating Income | First Reported 2003-03-31 | Previous Quarter -8.9 M | Current Value -8.7 M | Quarterly Volatility 6.6 M |
Check Oncternal Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncternal Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.8 M, Interest Expense of 847.7 K or Other Operating Expenses of 36.2 M, as well as many indicators such as Price To Sales Ratio of 38.14, Dividend Yield of 1.0E-4 or PTB Ratio of 1.0. Oncternal financial statements analysis is a perfect complement when working with Oncternal Therapeutics Valuation or Volatility modules.
Oncternal | Operating Income |
Latest Oncternal Therapeutics' Operating Income Growth Pattern
Below is the plot of the Operating Income of Oncternal Therapeutics over the last few years. Operating Income is the amount of profit realized from Oncternal Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Oncternal Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Oncternal Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncternal Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Oncternal Operating Income Regression Statistics
| Arithmetic Mean | (32,543,647) | |
| Coefficient Of Variation | (38.75) | |
| Mean Deviation | 9,240,204 | |
| Median | (33,108,000) | |
| Standard Deviation | 12,609,263 | |
| Sample Variance | 159T | |
| Range | 48.9M | |
| R-Value | (0.35) | |
| Mean Square Error | 150.7T | |
| R-Squared | 0.12 | |
| Significance | 0.21 | |
| Slope | (976,364) | |
| Total Sum of Squares | 2225.9T |
Oncternal Operating Income History
Other Fundumenentals of Oncternal Therapeutics
Oncternal Therapeutics Operating Income component correlations
Click cells to compare fundamentals
About Oncternal Therapeutics Financial Statements
Oncternal Therapeutics shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Oncternal Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Oncternal Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Oncternal Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -41.7 M | -43.8 M | |
| Non Operating Income Net Other | 903.9 K | 503.1 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.